research_innovation photo

Clinical Trials Information For Patients and Physicians

 

IG1102: A prospective, single-blind, randomized, phase III study to evaluate the safety and efficacy of Fibrin Sealant Grifols (FS Grifols) as an adjunct to hemostasis during Parenchymous Tissue open surgeries.

Principal Investigator:  Joseph Buell, MD

  • Patients are eligible if they require open liver resection surgery.

IG1101:  A prospective, single-blind, randomized, phase III study to evaluate the safety and efficacy of Fibrin Sealant Grifols (FS Grifols) as an adjunct to hemostasis during Peripheral Vascular Surgery.

Principal Investigator:  Anil Paramesh, MD

  • Patients are eligible if they require peripheral vascular procedures including upper extremity dialysis access and bypass grafting.

Sample Collection Cyclosporine.

Principal Investigator:  Anil Paramesh, MD

  • Patients are eligible if they have received a kidney or liver transplant and are currently taking Cyclosporine.


Multicenter, Double-Blind Placebo-Controlled Study of PRT-201 Administered Immediately after Radiocephalic Fistula Creation in Patients with Chronic Kidney Disease.

Principal Investigator:  Albert Sam, MD

  • Patients are eligible if they require AV Fistula placement in the wrist for dialysis access

For More Information on the trials listed above, please contact:

Tara Dobson
(504) 988-8260
tmancuso@tulane.edu

Corey Lach
(504)988-5272
clach@tulane.edu

Ruth Anna Wanstrath
(504) 988-8687
rwanstra@tulane.edu



E5501-G000-311: A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure.

Principal Investigator: Fredric Regenstein, MD

  • Patients are eligible if they a platelet count of <50 and require a surgical procedure.

A Multi-center, Double-Blind, Sponsor-Open Trial of IDN-6556 in Subjects Who had Hepatitis C Virus (HCV) Reinfection and Liver Fibrosis Following Orthotopic Liver Transplantation for Chronic HCV Infection and Who Subsequently Achieved a Sustained Virologic Response Following anti-HCV Therapy

Principal Investigator: Fredric Regenstein, MD

  • Patients are eligible if they have received a liver transplant and successfully completed Hepatitis C treatment.

For More Information on the trials listed above, please contact:

Delainna Bartholomew
(504) 988-6902
dbartho@tulane.edu

Nicole Lassair
(504) 988-2882
nlassair@tulane.edu